The agreement with PerkinElmer's Wallac Oy subsidiary will bring Mobidiag's real-time PCR-based gastrointestinal tests to a new market.
Executives provided updates on their companies at the 35th Annual JP Morgan Healthcare Conference in San Francisco.
Tulip Diagnostics Private provides in vitro diagnostic reagents, kits, and instruments to labs, and government and private healthcare facilities in India.
The companies will merge 10x's Chromium system and PerkinElmer's automation solutions into a combined NGS solution for researchers.
The company said the divestiture to Varian Medical Systems would allow it to concentrate on investing in high-growth parts of its business.
The company reported drops in revenues for both its human health and environmental health units, blaming challenging market conditions for the decreases.
Several academic and commercial groups are developing clinical cell-based noninvasive prenatal tests, which could eventually compete with current cell-free NIPTs.
The company said the diagnostics unit will be focused on reproductive health, diagnostics for emerging markets, and applied genomics.
The company said it will use the proceeds for various purposes, including working capital, capital expenditures, stock repurchases, dividends, and acquisitions.
Revenues rose thank to an increase in the company's human health business, which offset a decline in its environmental health segment.
In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.
Technology Review points out that a new US presidential science advisor hasn't been selected.
Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.
President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.